CARMAT has announced that its Board of Directors has decided to co-opt Jean-Luc Lemercier and Dr. Michael Mack as independent directors, thus replacing Marcello Conviti and André-Michel Ballester, who have stood down, for the remainder of their mandates, i.e. until the conclusion of the shareholders’ meeting called to rule on the company’s 2021 annual accounts. Mr. Jean-Luc Lemercier has been the Vice-President Transcatheter Heart Valve EMEA at Edwards Lifesciences since 2008. He has over 20 years of experience and acknowledged leadership in the medical device industry. During his career, Mr. Lemercier has held a number of strategic positions in cardiology sector, notably at Johnson & Johnson Cordis (1996-2008), where he created and headed, among other activities, the Structural Heart Disease division. Michael Mack is an internationally recognized American cardiac surgeon with long standing expertise in the introduction of innovative medical devices and procedures in cardiovascular disease. He is the author of more than 500 scientific publications and has received the Presidential Citation of the American College of Cardiology and the Transcatheter Cardiovascular Therapeutics (TCT) Lifetime Achievement Award. He is currently the Director of the Cardiovascular Service Line for the Baylor Scott & White Health in Dallas (Texas), a Director of the American Board of Thoracic Surgery and a member of the FDA MDEpiNet Advisory Committee1.